# Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

> **NCT06683950** · PHASE4 · RECRUITING · sponsor: **Kim's Eye Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Age-related Macular Degeneration (ARMD)

## Interventions

- **DRUG:** Aflibercept 8mg

## Key facts

- **NCT ID:** NCT06683950
- **Lead sponsor:** Kim's Eye Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-21
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06683950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06683950, "Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06683950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*